Autopsy report · NCT02468583
Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee
Cause of deathNo reason given
Life of this trial
- Registered 3 months after it had already started.
- Ran for about 1 year 5 months before it stopped.
- 6 participants enrolled.
- Results were posted on the registry 1 year 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Pacira Pharmaceuticals, Inc
- Sponsor type
- Industry
- Conditions
- Post-traumatic Osteoarthritis of the Knee
- Interventions
- FX006 32 mg; TCA IR 40 mg
- Participants
- 6
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.